By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Mersana Therapeutics, Inc. 

840 Memorial Drive
2nd Floor
Cambridge  Massachusetts  02139  U.S.A.
Phone: n/a Fax: n/a



Company News
Mersana Therapeutics' Lead Fleximer Immunoconjugate Demonstrates Potent Activity In Low HER2-Expressing Tumor Models 4/17/2015 2:51:12 PM
Mersana Therapeutics To Present Late-Breaking Poster At American Association for Cancer Research Annual Meeting 2015 4/15/2015 7:16:31 AM
Mersana Therapeutics Nabs $35 Million And A New CEO 3/2/2015 10:44:14 AM
Mersana Therapeutics, Inc., Takeda Pharmaceutical Co. Ltd. (TKPYY) Expand Antibody-Drug Pact By $300 Million 1/12/2015 6:17:41 AM
Mersana Therapeutics, Inc. And Takeda Pharmaceutical Co. Ltd. (TKPYY) Enter Commercial License Agreement For Novel Fleximer┬« Antibody-Drug Conjugate 10/27/2014 10:47:56 AM
Mersana Therapeutics, Inc. And Takeda (TKPYY) Enter Commercial License Agreement For Novel Fleximer® Antibody-Drug Conjugate 10/27/2014 10:24:35 AM
Mersana Therapeutics, Inc. Strengthens Antibody-Drug Conjugate Intellectual Property Position With Issuance Of Three Additional U.S. Patents 9/9/2014 10:57:39 AM
Cambridge-Based Mersana Therapeutics, Inc. Strikes New Oncology Pact Worth $792 Million With Merck KGaA (MKGAF.PK) 6/24/2014 6:59:25 AM
Mersana Therapeutics, Inc. Enters Collaboration With Takeda Pharmaceutical Co. Ltd. (TKPYY) To Develop Next-Generation Antibody-Drug Conjugates 4/7/2014 10:08:46 AM
Mersana Therapeutics, Inc. Awarded Patent With Broad Coverage For Fleximer-ADC Platform Technology 4/2/2014 9:55:20 AM